FATE
Fate Therapeutics
--
--(--)
Market Open: --
--
--(--)
Post-Market: --
FATE Profile
Fate Therapeutics, Inc.
A clinical-stage biopharmaceutical company that developing programmed cellular immunotherapies for the treatment of cancer diseases
Pharmaceutical
04/27/2007
10/01/2013
NASDAQ Stock Exchange
181
12-31
Common stock
12278 Scripps Summit Drive, San Diego, California 92131
--
Fate Therapeutics, Inc., merged in Delaware on April 27, 2007, is a clinical staging biopharmaceutical company dedicated to the exploration and development of adult stem cell therapy modulators for the treatment of rare diseases, including some malignant hematological diseases, lysosomal storage disorder and muscular dystrophy. Some of the new approaches used by Fate take existing therapeutic models, including small molecules and therapeutic proteins, and target good biological mechanisms to enhance the efficacy of adult stem cells.